U.S. stocks down for 10th straight session: What market insiders are saying

Category: Finance

U.S. stocks experienced significant declines following the Federal Reserve's interest rate cut and projections indicating a slower pace of future cuts. The S&P 500 fell 2.96%, the Nasdaq Composite dropped 3.62%, and the Dow Jones Industrial Average decreased by 2.61%. Market insiders expressed concerns over inflation and uncertainty, suggesting that the Fed's cautious stance has led to increased selling pressure in the markets.

Keywords: U.S. stocks, Federal Reserve, interest rates

Source: NorthJersey.com

Update At: 12/19/2024

Related Sources

15 Analysts Have This To Say About Blueprint Medicines - Blueprint Medicines (NASDAQ:BPMC)

Fifteen analysts provided mixed ratings for Blueprint Medicines, with an average 12-month price target of $116.47, reflecting an 18.93% increase from the previous target. Analysts' evaluations indicate a positive revenue trend, strong financial metrics, and a prudent debt management strategy, positioning the company favorably in the biopharmaceutical sector.

Benzinga

How To Trade (BPMC)

Trading strategies for Blueprint Medicines Corporation (BPMC) suggest buying near support levels of 105.22 and 111.23, with upside targets of 115.91 and 115.3 respectively. Short signals are indicated near resistance levels of 115.91 and 115.3, with downside targets of 105.22 and 109.84. Stop losses are recommended to manage risk effectively.

Stock Traders Daily

Blueprint Medicines (NASDAQ:BPMC) PT Raised to $138.00

Guggenheim raised the price target for Blueprint Medicines from $130 to $138, maintaining a buy rating. Other analysts have also increased their price targets, with a consensus rating of Moderate Buy and an average price target of $120. The company reported earnings of ($0.80) per share, beating estimates, and revenue of $138.20 million, up 139.9% year-over-year. Insider trading activity has seen significant share sales, and institutional investors have adjusted their positions in the company.

MarketBeat

Needham & Company LLC Reiterates "Buy" Rating for Blueprint Medicines (NASDAQ:BPMC)

Blueprint Medicines has received a 'buy' rating from Needham & Company with a price target of $130.00, indicating a potential upside of 29.62%. Other analysts have set various price targets, with an average target of $118.33. The company's stock has seen significant trading activity and has a market capitalization of $6.28 billion. Blueprint Medicines reported earnings of ($1.32) per share, beating estimates, and had revenue of $96.12 million for the last quarter. Insiders have sold a total of 130,064 shares in the last 90 days.

MarketBeat

Blueprint Medicines (NASDAQ:BPMC) Price Target Raised to $105.00

Barclays raised its price target for Blueprint Medicines from $75.00 to $105.00, maintaining an 'equal weight' rating. Other analysts have set higher targets, with Stephens at $140.00 and Needham at $130.00. The stock has an average rating of 'Moderate Buy' and a price target of $118.33. Recently, BPMC shares traded at $110.34, with a market cap of $6.91 billion. The company reported earnings of ($1.32) per share, exceeding estimates, and had revenue of $96.12 million for the last quarter. Insider trading activity has been noted, with significant shares sold recently.

MarketBeat

Japan’s Topix, Nikkei Stock Gauges Tumble 20% From July Peaks

Japan's equity benchmarks, including the Topix and Nikkei 225, fell over 20% from record highs due to declining investor confidence, a stronger yen, tighter monetary policy, and a worsening economic outlook in the US. Both indices experienced significant declines, marking the worst performance since the 2011 Fukushima disaster.

Bloomberg

Japan's Nikkei 225 index plunges nearly 7% as global sell-offs resume

Japan's Nikkei 225 stock index fell 6.7% early Monday, continuing a sell-off that began last week due to concerns over the U.S. economy and high interest rates. The index dropped significantly after a disappointing U.S. hiring report, leading to global market declines. The Bank of Japan's recent interest rate hike has also contributed to the Nikkei's struggles, impacting exporters and tourism.

The Detroit News

Tech stocks see steepest three-week slump in two years, led by plunge in Amazon and Intel

Wall Street is experiencing anxiety as the Nasdaq Composite fell 3.4% this week, marking an 8.8% decline over three weeks, the worst since September 2022. Disappointing earnings from major tech companies like Amazon and Microsoft, alongside concerns about the U.S. economy, have contributed to this downturn. Amazon's revenue shortfall is attributed to consumers opting for cheaper goods, while Apple showed modest growth. Meta's stock rose after beating estimates, but Nvidia's upcoming earnings report is highly anticipated amidst its significant stock fluctuations. Intel faced a severe drop after a major earnings miss and announced a significant workforce reduction.

CNBC

Is it the end of the road for the 'Magnificent Seven'?

The 'Magnificent Seven' stocks, which include Meta, Amazon, Microsoft, Alphabet, Apple, Tesla, and Nvidia, have experienced a significant selloff after a period of remarkable growth driven by AI optimism. Following disappointing earnings reports, particularly from Tesla, the stocks collectively lost over $1.7 trillion in market capitalization. The selloff has raised concerns about the sustainability of their growth amid rising interest rates and changing consumer spending patterns. Analysts suggest that the future path of interest rates will heavily influence market behavior, potentially leading to a broader distribution of investor interest across various stocks.

RTE.ie

2 Tech Stocks to Buy on the Dip Amid the Market Pullback

The recent technology-driven stock market selloff has led to significant declines in stocks like Uber Technologies and AppLovin, both trading at least 25% below their highs. Despite the downturn, Uber is projected to grow its revenue significantly and has a strong earnings outlook, while AppLovin is benefiting from AI-enhanced features and a rebound in digital advertising. Both companies are set to report earnings soon, presenting potential buying opportunities for investors.

Yahoo Finance